1-866-598-7166

9-ING-41 in Patients with Advanced Cancers

Trial ID: NCT03678883
Kidney Cancer Type: All subtype


Background:

A protein called GSK-3β plays a role in cancer by helping cancer cells grow, survive, and resist treatment. High levels of this protein have been found in many different cancers. 

9-ING-41 is a new type of drug that blocks GSK-3β. Earlier lab studies have found that this drug is able to slow or stop cancer growth, making cells more sensitive to chemotherapy. 

Since this drug is still in the clinical trial phase, it has the placeholder name 9-ING-41 rather than a commercial trade name.

 

The Trial:

This study is testing whether the new drug 9-ING-41, used alone or with chemotherapy, is safe and effective at slowing down or shrinking tumors that have stopped responding to standard treatments.

There are many different treatment regimes, and you will be randomized to one of them:

  • 9-ING-41 alone
  • 9-ING-41 + Gemcitabine
  • 9-ING-41 + Doxorubicin
  • 9-ING-41 + Lomustine
  • 9-ING-41 + Carboplatin
  • 9-ING-41 + Nab-paclitaxel + Gemcitabine
  • 9-ING-41 + Paclitaxel + Carboplatin
  • 9-ING-41 + Irinotecan

This trial is not “blinded”, which means both you and your doctor will know which treatment you are receiving.

 

Basic Eligibility:

  • Advanced or metastatic kidney cancer (solid tumors)
  • No longer responding to current treatments, relapsed, or has no standard treatment options left that can be used.

Additional eligibility criteria will apply. Please speak to your doctor.

Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentreCross Cancer Institute Principal InvestigatorNot Given LocationEdmonton, AB Trial StatusActive, Not Recruiting
Hospital / Cancer CentreQE II Health Sciences Centre Principal InvestigatorNot Given LocationHalifax, NS Trial StatusActive, Not Recruiting
Hospital / Cancer CentreCentre Intégré de Santé et de Services Sociaux de la Montérégie-Centre Principal InvestigatorNot Given LocationGreenfield Park, QC Trial StatusActive, Not Recruiting
Hospital / Cancer CentreJewish General Hospital Principal InvestigatorNot Given LocationMontreal, QC Trial StatusActive, Not Recruiting
Hospital / Cancer CentreMcGill University Health Centre Principal InvestigatorNot Given LocationMontreal, QC Trial StatusActive, Not Recruiting
Hospital / Cancer CentreCentre Hospitalier Universitaire de Sherbrooke Principal InvestigatorNot Given LocationSherbrooke, QC Trial StatusActive, Not Recruiting
Kidney Cancer Canada